Study examines probiotic use in preventing gastrointestinal disorders in infants

January 13, 2014

Giving an infant a probiotic during the first three months of life appears to reduce the onset of gastrointestinal disorders and result in lower associated costs, according to a study by Flavia Indrio, M.D., of the Aldo Moro University of Bari, Italy, and colleagues.

Infant colic, acid reflux and constipation are the most common gastrointestinal disorders that lead to a pediatrician referral during the first six months of life. They are often responsible for hospitalization, feeding changes, use of drugs, parental anxiety and loss of parental working days, according to the study background.

Researchers randomized 554 newborns in nine pediatric units in Italy to the probiotic Lactobacillus reuteri DSM 17938 (L reuteri DSM 17938) or placebo for 90 days, and asked parents to record in diary entries the number of vomiting episodes and evacuations (emptying of the bowels), the duration of inconsolable crying and the number of pediatrician visits. Change in daily crying time, vomiting, constipation and the cost benefits of probiotic supplement use was measured during the three month period.

At three months of age, the average duration of crying time (38 vs. 71 minutes), regurgitations (2.9 vs. 4.6) and evacuations per day (4.2 vs. 3.6) differed in the probiotic and placebo groups, respectively. Probiotic use also was associated with a nearly $119 average savings per patient in each family.

"Driving a change of colonization during the first weeks of life through giving lactobacilli may promote an improvement in intestinal permeability; visceral sensitivity and mast cell density and probiotic administration may represent a new strategy for preventing these conditions, at least in predisposed children," the authors conclude.
-end-
(JAMA Pediatr. Published online January 13, 2014. doi:10.1001/jamapediatrics.2013.4367. Available pre-embargo to the media at http://media.jamanetwork.com.)

Editor's Note: This study was supported by BioGaia AB in Sweden. Please see article for additional information, including other authors, author contributions and affiliations, etc.

The JAMA Network Journals

Related Placebo Articles from Brightsurf:

Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.

Hydroxychloroquine no more effective than placebo in preventing COVID-19
Clinical trial with COVID-19 testing of participants shows health care workers in contact with coronavirus patients who took hydroxychloroquine each day did not reduce their rate of infection.

Compared to placebo, vitamin D has no benefit for severe asthma attacks
Contrary to earlier observational results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

UMN trial shows hydroxychloroquine has no benefit over placebo in preventing COVID-19
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

The placebo effect and psychedelic drugs: tripping on nothing?
A new study from McGill suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone.

Methotrexate reduces joint damage progression over placebo in erosive hand OA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis, but did significantly reduce the progression of joint damage over placebo and seems to facilitate bone remodeling in these patients.

Botulinum toxin reduces chronic migraine attacks, compared to placebo
A growing body of evidence supports the effectiveness of botulinum toxin injections in reducing the frequency of chronic migraine headaches, concludes an updated review and analysis in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Opioids vs. placebo, nonopioid alternatives for chronic noncancer pain
An estimated 50 million adults in the United States were living with chronic noncancer pain in 2016 and many of them were prescribed opioid medications, even though a clinical benefit is uncertain.

Probiotic no better than placebo for acute gastroenteritis in children
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.

Most common shoulder operation is no more beneficial than placebo surgery
In a landmark study published this week in the BMJ, Finnish researchers show that one of the most common surgical procedures in the Western world is probably unnecessary.

Read More: Placebo News and Placebo Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.